Concepedia

Author

William J. Kell

Leicester Royal Infirmary

Also Known As

W J Kell, W. J. Kell, W. Jonathan Kell, W.J. Kell, William J. Kell

16

Publications

936

Citations

7

H-Index

6

Concepts

All Affiliations

Leicester Royal InfirmaryHeartlands HospitalUniversity Hospital of WalesUniversity of BirminghamCardiff University
WJ

About

William J. Kell is an author at Leicester Royal Infirmary specializing in hematology, pharmacotherapy, and cancer research.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

1

1

158

2

Immunology

1

1

158

3

Hematology

1

1

158

4

Cancer Research

1

1

158

5

Oncology

1

1

158

William J. Kell

×

6

Publications

898

Citations

6

H-Index

YearCitations

A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy

Steven Knapper, Alan K. Burnett, Tim Littlewood,

Blood

2006

393

A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia

William J. Kell

Blood

2003

180

The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison

Alan K. Burnett, Robert K. Hills, Ann E. Hunter,

Leukemia

2012

158

The Addition of Gemtuzumab Ozogamicin to Induction Chemotherapy for AML Improves Disease Free Survival without Extra Toxicity: Preliminary Analysis of 1115 Patients in the MRC AML15 Trial.

Alan K. Burnett, William J. Kell, Anthony H. Goldstone,

Blood

2006

78

Photosensitivity and acute liver injury in myeloproliferative disorder secondary to late-onset protoporphyria caused by deletion of a ferrochelatase gene in hematopoietic cells

Richard G. Goodwin, William J. Kell, P. Laidler,

Blood

2005

60

The Addition of Gemtuzumab Ozogamicin to Intensive Chemotherapy in Older Patients with AML Produces a Significant Improvement in Overall Survival: Results of the UK NCRI AML16 Randomized Trial

Alan K. Burnett, Robert K. Hills, Ann E. Hunter,

Blood

2011

29

Page 1